MA37455B1 - Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique - Google Patents
Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chroniqueInfo
- Publication number
- MA37455B1 MA37455B1 MA37455A MA37455A MA37455B1 MA 37455 B1 MA37455 B1 MA 37455B1 MA 37455 A MA37455 A MA 37455A MA 37455 A MA37455 A MA 37455A MA 37455 B1 MA37455 B1 MA 37455B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- acute exacerbations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'utilisation de 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-méthylbenzamide ou d'un dérivé pharmaceutiquement acceptable de celui-ci dans la fabrication d'un médicament pour le traitement d'exacerbations aiguës d'une maladie pulmonaire obstructive chronique. Le traitement peut comprendre une dose unique du principe actif par administration par voie orale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261613187P | 2012-03-20 | 2012-03-20 | |
PCT/EP2013/055730 WO2013139809A1 (fr) | 2012-03-20 | 2013-03-19 | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37455A1 MA37455A1 (fr) | 2016-08-31 |
MA37455B1 true MA37455B1 (fr) | 2017-03-31 |
Family
ID=47901996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37455A MA37455B1 (fr) | 2012-03-20 | 2013-03-19 | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique |
Country Status (30)
Country | Link |
---|---|
US (2) | US9339491B2 (fr) |
EP (1) | EP2827860B1 (fr) |
JP (1) | JP6091593B2 (fr) |
KR (1) | KR101793777B1 (fr) |
CN (1) | CN104203234B (fr) |
AU (1) | AU2013237503B2 (fr) |
BR (1) | BR112014023107B1 (fr) |
CA (1) | CA2866108C (fr) |
CL (1) | CL2014002471A1 (fr) |
CY (1) | CY1118327T1 (fr) |
DK (1) | DK2827860T3 (fr) |
ES (1) | ES2605942T3 (fr) |
HK (1) | HK1200352A1 (fr) |
HR (1) | HRP20161514T1 (fr) |
HU (1) | HUE032004T2 (fr) |
IL (1) | IL234537A (fr) |
LT (1) | LT2827860T (fr) |
MA (1) | MA37455B1 (fr) |
MX (1) | MX351996B (fr) |
NZ (1) | NZ628392A (fr) |
PH (1) | PH12014502107B1 (fr) |
PL (1) | PL2827860T3 (fr) |
PT (1) | PT2827860T (fr) |
RU (1) | RU2625762C2 (fr) |
SG (1) | SG11201404941WA (fr) |
SI (1) | SI2827860T1 (fr) |
TN (1) | TN2014000350A1 (fr) |
TW (1) | TWI583381B (fr) |
WO (1) | WO2013139809A1 (fr) |
ZA (1) | ZA201405871B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2600822C1 (ru) * | 2015-09-03 | 2016-10-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) | Способ лечения хронического обструктивного бронхита |
RU2600833C1 (ru) * | 2015-09-03 | 2016-10-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) | Способ лечения хронической обструктивной болезни легких |
MX2018010781A (es) | 2016-03-08 | 2018-11-09 | Mereo Biopharma 1 Ltd | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias. |
BR112018067454A2 (pt) * | 2016-03-08 | 2019-01-15 | Mereo Biopharma 1 Ltd | regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica |
US10331542B2 (en) * | 2016-06-23 | 2019-06-25 | International Business Machines Corporation | System and method for detecting and alerting unexpected behavior of software applications |
GB201612238D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
GB201612240D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
KR20200067170A (ko) | 2017-10-05 | 2020-06-11 | 풀크럼 쎄러퓨틱스, 인코포레이티드 | FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제 |
KR20200097310A (ko) | 2017-12-11 | 2020-08-18 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화의 예방 또는 감소에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도 |
KR20200097311A (ko) | 2017-12-11 | 2020-08-18 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2298743T1 (sl) | 2003-06-26 | 2012-12-31 | Novartis Ag | Inhibitorji p38-kinaze na osnovi 5-ÄŤlenskih heterociklov |
GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
-
2013
- 2013-03-19 WO PCT/EP2013/055730 patent/WO2013139809A1/fr active Application Filing
- 2013-03-19 KR KR1020147025904A patent/KR101793777B1/ko active IP Right Grant
- 2013-03-19 EP EP13710851.0A patent/EP2827860B1/fr active Active
- 2013-03-19 SI SI201330397A patent/SI2827860T1/sl unknown
- 2013-03-19 HU HUE13710851A patent/HUE032004T2/en unknown
- 2013-03-19 NZ NZ628392A patent/NZ628392A/en unknown
- 2013-03-19 JP JP2015500892A patent/JP6091593B2/ja active Active
- 2013-03-19 BR BR112014023107-9A patent/BR112014023107B1/pt active IP Right Grant
- 2013-03-19 AU AU2013237503A patent/AU2013237503B2/en active Active
- 2013-03-19 MA MA37455A patent/MA37455B1/fr unknown
- 2013-03-19 ES ES13710851.0T patent/ES2605942T3/es active Active
- 2013-03-19 DK DK13710851.0T patent/DK2827860T3/en active
- 2013-03-19 SG SG11201404941WA patent/SG11201404941WA/en unknown
- 2013-03-19 MX MX2014011291A patent/MX351996B/es active IP Right Grant
- 2013-03-19 TW TW102109739A patent/TWI583381B/zh active
- 2013-03-19 PL PL13710851T patent/PL2827860T3/pl unknown
- 2013-03-19 CA CA2866108A patent/CA2866108C/fr active Active
- 2013-03-19 LT LTEP13710851.0T patent/LT2827860T/lt unknown
- 2013-03-19 CN CN201380015703.5A patent/CN104203234B/zh active Active
- 2013-03-19 US US14/386,174 patent/US9339491B2/en active Active
- 2013-03-19 PT PT137108510T patent/PT2827860T/pt unknown
- 2013-03-19 RU RU2014141893A patent/RU2625762C2/ru active
-
2014
- 2014-08-11 ZA ZA2014/05871A patent/ZA201405871B/en unknown
- 2014-08-11 TN TNP2014000350A patent/TN2014000350A1/fr unknown
- 2014-09-08 IL IL234537A patent/IL234537A/en active IP Right Grant
- 2014-09-17 CL CL2014002471A patent/CL2014002471A1/es unknown
- 2014-09-22 PH PH12014502107A patent/PH12014502107B1/en unknown
-
2015
- 2015-01-29 HK HK15101000.9A patent/HK1200352A1/zh unknown
-
2016
- 2016-04-29 US US15/143,356 patent/US20160243081A1/en not_active Abandoned
- 2016-11-16 HR HRP20161514TT patent/HRP20161514T1/hr unknown
- 2016-11-18 CY CY20161101194T patent/CY1118327T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37455B1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
JP2016053040A5 (fr) | ||
MX2018002631A (es) | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
JP2016528301A5 (fr) | ||
JP2016517888A5 (fr) | ||
BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
AR100663A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
MX2018010782A (es) | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. | |
PH12021550170A1 (en) | Pharmaceutical dosage form which can be adminitered orally and has modified release | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
JP2019507786A5 (fr) | ||
WO2015047982A3 (fr) | Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions | |
MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
AR088844A1 (es) | Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida | |
MA50458A (fr) | Formulations topiques destinées au traitement d'affections dermatologiques comprenant la calvitie hippocratique | |
EP4052699A4 (fr) | Médicament sous forme pharmaceutique solide administré par voie orale | |
JP2016505628A5 (fr) | ||
FI3903774T3 (fi) | N,N-bis-2-merkaptoetyyli-isoftalamidi neurodegeneratiivisten sairauksien hoitoon | |
PH12016500716A1 (en) | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate | |
MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
TH183323B (th) | สูตรที่ให้ทางปากของดีฟีราซิรอกซ์ (deferasirox) | |
TH161044B (th) | ไทร(เฮเทอโร)เอริล ไพราโซล และการใช้ของมัน |